Αποτελέσματα Αναζήτησης
Menveo is indicated for active immunization of children (from 2 years of age), adolescents and adults at risk of exposure to Neisseria meningitidis groups A, C, W-135 and Y, to prevent invasive disease.
A different meningococcal vaccine is available that can help protect against serogroup B. Meningococcal disease can cause meningitis (infection of the lining of the brain and spinal cord) and infections of the blood.
6 Αυγ 2021 · Download and print official up-to-date meningococcal ACWY VISs in English and Spanish, plus other languages. PDF format.
Menveo is indicated for active immunisation of children (from two years of age), adolescents and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease. The use of this vaccine should be in accordance with official recommendations.
MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55...
Menveo is now available in two presentations: • Two-vial (requires reconstitution) Recommended for ages 2 months and older* • Single-vial (ready-to-use) Recommended for ages 10 years and older NOT for use in individuals before their 10th birthday • To extend existing stocks of MenACWY vaccine products, CDC recommends that health care ...
17 Οκτ 2022 · The Menveo vaccine (supplied in a two-vial presentation) for meningococcal groups A, C, Y, and W has been approved in over 60 countries, with more than 72 million doses distributed worldwide since 2010. It offers extensive evidence of immunogenicity and a well-characterised safety profile.
